These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 11200055)

  • 21. CD2-CD48 interactions promote cytotoxic T lymphocyte induction and function: anti-CD2 and anti-CD48 antibodies impair cytokine synthesis, proliferation, target recognition/adhesion, and cytotoxicity.
    Musgrave BL; Watson CL; Hoskin DW
    J Interferon Cytokine Res; 2003 Feb; 23(2):67-81. PubMed ID: 12744772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD28 ligation by monoclonal antibodies or B7/BB1 provides an accessory signal for the cyclosporin A-resistant generation of cytotoxic T cell activity.
    Van Gool SW; de Boer M; Ceuppens JL
    J Immunol; 1993 Apr; 150(8 Pt 1):3254-63. PubMed ID: 7682237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenosine inhibits activation-induced T cell expression of CD2 and CD28 co-stimulatory molecules: role of interleukin-2 and cyclic AMP signaling pathways.
    Butler JJ; Mader JS; Watson CL; Zhang H; Blay J; Hoskin DW
    J Cell Biochem; 2003 Aug; 89(5):975-91. PubMed ID: 12874832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of cell cycle progression by CTLA4-CD80/CD86 interactions on CD4+ T cells depends on strength of the CD3 signal: critical role for IL-2.
    Mukherjee S; Ahmed A; Malu S; Nandi D
    J Leukoc Biol; 2006 Jul; 80(1):66-74. PubMed ID: 16624934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Signaling via CD28 costimulates lymphokine production, but does not reverse unresponsiveness to interleukin-2 in anti-CD3 triggered Th1 cells.
    Sommer F; Röllinghoff M; Lohoff M
    Eur J Immunol; 1993 Oct; 23(10):2498-502. PubMed ID: 8405051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity.
    Pouw N; Treffers-Westerlaken E; Mondino A; Lamers C; Debets R
    Mol Immunol; 2010 Apr; 47(7-8):1411-20. PubMed ID: 20303179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
    Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
    Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of alloreactive cytolytic T lymphocytes by immobilized anti-CD3 monoclonal antibodies. Analysis of requirements for human cytolytic T-lymphocyte differentiation.
    De Jong R; Brouwer M; Rebel VI; Van Seventer GA; Miedema F; Van Lier RA
    Immunology; 1990 Jul; 70(3):357-64. PubMed ID: 2143171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads.
    Teschner D; Wenzel G; Distler E; Schnürer E; Theobald M; Neurauter AA; Schjetne K; Herr W
    Scand J Immunol; 2011 Aug; 74(2):155-64. PubMed ID: 21517928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential regulatory signals delivered by antibody binding to the CD28 (Tp44) molecule during the activation of human T lymphocytes.
    Damle NK; Doyle LV; Grosmaire LS; Ledbetter JA
    J Immunol; 1988 Mar; 140(6):1753-61. PubMed ID: 2964482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for a critical role for IL-2 in CD40-mediated activation of naive B cells by primary CD4 T cells.
    Johnson-Léger C; Christenson JR; Holman M; Klaus GG
    J Immunol; 1998 Nov; 161(9):4618-26. PubMed ID: 9794390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
    Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
    Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
    Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12.
    Okamoto I; Kohno K; Tanimoto T; Ikegami H; Kurimoto M
    J Immunol; 1999 Mar; 162(6):3202-11. PubMed ID: 10092771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of NF-kappa B nuclear activity in peripheral blood mononuclear cells: role of CD28 antigen.
    Romano MF; Bisogni R; Lamberti A; Turco MC; Petrella A; Tassone P; Van Lier R; Formisano S; Venuta S
    Cell Immunol; 1994 Jul; 156(2):371-7. PubMed ID: 8025954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenotypic and functional modulation of interleukin-2-activated peripheral blood mononuclear cells by anti-CD3 and anti-CD28 antibody.
    Yoshino I; Yano T; Miyamoto M; Sugimachi K; Kimura G; Nomoto K
    Lymphokine Cytokine Res; 1993 Aug; 12(4):191-6. PubMed ID: 8218591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Requirements for CD28-dependent T cell-mediated cytotoxicity.
    Azuma M; Cayabyab M; Phillips JH; Lanier LL
    J Immunol; 1993 Mar; 150(6):2091-101. PubMed ID: 8383716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10.
    Schandené L; Alonso-Vega C; Willems F; Gérard C; Delvaux A; Velu T; Devos R; de Boer M; Goldman M
    J Immunol; 1994 May; 152(9):4368-74. PubMed ID: 7512591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation.
    Yang G; Hellström KE; Mizuno MT; Chen L
    J Immunol; 1995 Oct; 155(8):3897-903. PubMed ID: 7561096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.